OpenAI’s GPT just did something that should make every drug patent strategist sit up: it reportedly “smashed” drug patent cliffs—by accelerating the work that used to take teams months, sometimes years, to complete.
That’s the claim behind the latest b…

Predict the Attack: How to Forecast Paragraph IV Filings and Neutralize “Skinny Label” Threats
In the pharmaceutical industry, the most expensive surprises rarely arrive with a press release. They arrive quietly—months after a competitor has already ma…

Drug patents don’t just “expire”—they run a clock. And in the GCC, that clock can decide who wins the next market cycle.
If you’re a brand company, a generic player, an investor, or a legal team advising on launch timing, you already know the headline:…

Unlocking the Hidden Timeline: How Long Do Drug Patents Last in the GCC?
Imagine investing millions into developing a groundbreaking medication, only to find out that your exclusive rights could expire sooner than expected, or worse, that your competit…

Your competitor isn’t “just being patient.” They’re often extending the life of a drug—quietly, legally, and with a playbook that looks like innovation from the outside.
In pharma, the most consequential battles rarely happen at the headline level. The…

Biopharma teams don’t lose deals because they lack ambition. They lose because they’re late.
Late to the science. Late to the market. Late to the paperwork. And—more often than most executives want to admit—late to the packaging strategy that determine…

OpenAI’s “GPT for Life Sciences” is getting the headlines—but the real question for drug developers isn’t whether the model is impressive. It’s whether it changes the economics of discovery.
Because in pharma, the bottleneck isn’t curiosity. It’s cost,…

Patent expiry intelligence isn’t just for lawyers—it’s for operators.
Most biosimilar strategies fail for a simple reason: they’re built on timing that’s already gone. Teams map patent cliffs, model launch windows, and wait for the “right” moment—onl…

Europe’s drug patent clock is ticking—and most people misunderstand where it actually runs out.
If you’re building a pipeline, underwriting risk, or planning market entry, “patent protection lasts X years” is the kind of sentence that sounds precise… u…

Drug discovery timelines are quietly getting longer—until they suddenly don’t.
For years, the industry has treated time-to-candidate as an unavoidable tax: target identification, assay development, screening, hit-to-lead optimization, iteration cycles,…